Transcriptional reprogramming during human osteoclast differentiation identifies regulators of osteoclast activity.
Journal
Bone research
ISSN: 2095-4700
Titre abrégé: Bone Res
Pays: China
ID NLM: 101608652
Informations de publication
Date de publication:
24 Jan 2024
24 Jan 2024
Historique:
received:
05
07
2023
accepted:
15
12
2023
revised:
08
11
2023
medline:
24
1
2024
pubmed:
24
1
2024
entrez:
23
1
2024
Statut:
epublish
Résumé
Enhanced osteoclastogenesis and osteoclast activity contribute to the development of osteoporosis, which is characterized by increased bone resorption and inadequate bone formation. As novel antiosteoporotic therapeutics are needed, understanding the genetic regulation of human osteoclastogenesis could help identify potential treatment targets. This study aimed to provide an overview of transcriptional reprogramming during human osteoclast differentiation. Osteoclasts were differentiated from CD14
Identifiants
pubmed: 38263167
doi: 10.1038/s41413-023-00312-6
pii: 10.1038/s41413-023-00312-6
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
5Subventions
Organisme : Lundbeckfonden (Lundbeck Foundation)
ID : R335-2019-2195
Organisme : Lundbeckfonden (Lundbeck Foundation)
ID : R335-2019-2195
Organisme : Novo Nordisk Fonden (Novo Nordisk Foundation)
ID : NNF18OC0052699
Organisme : Novo Nordisk Fonden (Novo Nordisk Foundation)
ID : NNF18OC0055047
Organisme : Wellcome Trust (Wellcome)
ID : SBF004|1034
Organisme : Wellcome Trust (Wellcome)
ID : 224155/Z/21/Z
Organisme : Odense Universitetshospital (Odense University Hospital)
ID : A3147
Informations de copyright
© 2024. The Author(s).
Références
Bolamperti, S., Villa, I. & Rubinacci, A. Bone remodeling: an operational process ensuring survival and bone mechanical competence. Bone Res. 10, 48 (2022).
pubmed: 35851054
pmcid: 9293977
doi: 10.1038/s41413-022-00219-8
Arai, F. et al. Commitment and differentiation of osteoclast precursor cells by the sequential expression of c-Fms and receptor activator of nuclear factor kappaB (RANK) receptors. J. Exp. Med. 190, 1741–1754 (1999).
pubmed: 10601350
pmcid: 2195707
doi: 10.1084/jem.190.12.1741
Li, X. et al. p38 MAPK-mediated signals are required for inducing osteoclast differentiation but not for osteoclast function. Endocrinology 143, 3105–3113 (2002).
pubmed: 12130576
doi: 10.1210/endo.143.8.8954
Moon, J. B. et al. Akt induces osteoclast differentiation through regulating the GSK3β/NFATc1 signaling cascade. J. Immunol. 188, 163–169 (2012).
pubmed: 22131333
doi: 10.4049/jimmunol.1101254
Takayanagi, H. et al. Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. Dev. Cell 3, 889–901 (2002).
pubmed: 12479813
doi: 10.1016/S1534-5807(02)00369-6
Boyle, W. J., Simonet, W. S. & Lacey, D. L. Osteoclast differentiation and activation. Nature 423, 337–342 (2003).
pubmed: 12748652
doi: 10.1038/nature01658
Simonet, W. S. et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 89, 309–319 (1997).
pubmed: 9108485
doi: 10.1016/S0092-8674(00)80209-3
D’Amelio, P. et al. Spontaneous osteoclast formation from peripheral blood mononuclear cells in postmenopausal osteoporosis. FASEB J. 19, 410–412 (2005).
pubmed: 15611151
Streicher, C. et al. Estrogen regulates bone turnover by targeting RANKL expression in bone lining cells. Sci. Rep. 7, 6460 (2017).
pubmed: 28744019
pmcid: 5527119
doi: 10.1038/s41598-017-06614-0
D’Amelio, P. et al. Estrogen deficiency increases osteoclastogenesis up-regulating T cells activity: a key mechanism in osteoporosis. Bone 43, 92–100 (2008).
pubmed: 18407820
doi: 10.1016/j.bone.2008.02.017
Eastell, R. et al. Postmenopausal osteoporosis. Nat. Rev. Dis. Primers. 2, 16069 (2016).
pubmed: 27681935
doi: 10.1038/nrdp.2016.69
Rizzoli, R. et al. Adverse reactions and drug-drug interactions in the management of women with postmenopausal osteoporosis. Calcif. Tissue Int. 89, 91–104 (2011).
pubmed: 21637997
pmcid: 3135835
doi: 10.1007/s00223-011-9499-8
Cipriani, C., Pepe, J., Minisola, S. & Lewiecki, E. M. Adverse effects of media reports on the treatment of osteoporosis. J. Endocrinol. Invest. 41, 1359–1364 (2018).
pubmed: 29761280
doi: 10.1007/s40618-018-0898-9
Pazianas, M. & Abrahamsen, B. Safety of bisphosphonates. Bone 49, 103–110 (2011).
pubmed: 21236370
doi: 10.1016/j.bone.2011.01.003
Fink, H. A. et al. Long-term drug therapy and drug discontinuations and holidays for osteoporosis fracture prevention: a systematic review. Ann. Intern. Med. 171, 37–50 (2019).
pubmed: 31009947
doi: 10.7326/M19-0533
Møller, A. M. J. et al. Fusion potential of human osteoclasts in vitro reflects age, menopause, and in vivo bone resorption levels of their donors-A possible involvement of DC-STAMP. Int. J. Mol. Sci. 21, 6368 (2020).
pubmed: 32887359
pmcid: 7504560
doi: 10.3390/ijms21176368
Hansen, M. S. et al. GIP reduces osteoclast activity and improves osteoblast survival in primary human bone cells. Eur. J. Endocrinol. 188, lvac004 (2023).
pubmed: 36747334
doi: 10.1093/ejendo/lvac004
Gallois, A. et al. Genome-wide expression analyses establish dendritic cells as a new osteoclast precursor able to generate bone-resorbing cells more efficiently than monocytes. J. Bone Miner. Res. 25, 661–672 (2010).
pubmed: 19775202
doi: 10.1359/jbmr.090829
Lee, B., Kim, J. H., Jung, J. H., Kim, T. H. & Ji, J. D. TREM-1, a negative regulator of human osteoclastogenesis. Immunol. Lett. 171, 50–59 (2016).
pubmed: 26852644
doi: 10.1016/j.imlet.2016.02.002
Rashid, S. et al. Identification of differentially expressed genes and molecular pathways involved in osteoclastogenesis using RNA-seq. Genes (Basel) 14, 916 (2023).
pubmed: 37107674
doi: 10.3390/genes14040916
Riihonen, R. et al. Membrane-bound carbonic anhydrases in osteoclasts. Bone 40, 1021–1031 (2007).
pubmed: 17291844
doi: 10.1016/j.bone.2006.11.028
Lehenkari, P., Hentunen, T. A., Laitala-Leinonen, T., Tuukkanen, J. & Vaananen, H. K. Carbonic anhydrase II plays a major role in osteoclast differentiation and bone resorption by effecting the steady state intracellular pH and Ca
pubmed: 9665810
doi: 10.1006/excr.1998.4071
Dai, R. et al. Cathepsin K: the action in and beyond bone. Front. Cell Dev. Biol. 8, 433 (2020).
pubmed: 32582709
pmcid: 7287012
doi: 10.3389/fcell.2020.00433
Hayman, A. R. Tartrate-resistant acid phosphatase (TRAP) and the osteoclast/immune cell dichotomy. Autoimmunity 41, 218–223 (2008).
pubmed: 18365835
doi: 10.1080/08916930701694667
Kikuta, J. & Ishii, M. Osteoclast migration, differentiation and function: novel therapeutic targets for rheumatic diseases. Rheumatology (Oxford) 52, 226–234 (2013).
pubmed: 23024017
doi: 10.1093/rheumatology/kes259
Destaing, O. et al. The tyrosine kinase activity of c-Src regulates actin dynamics and organization of podosomes in osteoclasts. Mol. Biol. Cell 19, 394–404 (2008).
pubmed: 17978100
pmcid: 2174183
doi: 10.1091/mbc.e07-03-0227
Arnett, T. R. Extracellular pH regulates bone cell function. J. Nutr. 138, 415S–418S (2008).
pubmed: 18203913
doi: 10.1093/jn/138.2.415S
Muñoz-Fuentes, V. et al. The International Mouse Phenotyping Consortium (IMPC): a functional catalogue of the mammalian genome that informs conservation. Conserv. Genet. 19, 995–1005 (2018).
pubmed: 30100824
pmcid: 6061128
doi: 10.1007/s10592-018-1072-9
Jemtland, R. et al. Molecular disease map of bone characterizing the postmenopausal osteoporosis phenotype. J. Bone Miner. Res. 26, 1793–1801 (2011).
pubmed: 21452281
doi: 10.1002/jbmr.396
Rumpler, M. et al. Osteoclasts on bone and dentin in vitro: mechanism of trail formation and comparison of resorption behavior. Calcif. Tissue Int. 93, 526–539 (2013).
pubmed: 24022329
pmcid: 3827903
doi: 10.1007/s00223-013-9786-7
Zhou, Y. et al. A novel approach for correction of crosstalk effects in pathway analysis and its application in osteoporosis research. Sci. Rep. 8, 668 (2018).
pubmed: 29330445
pmcid: 5766601
doi: 10.1038/s41598-018-19196-2
Liu, Y. Z. et al. Attenuated monocyte apoptosis, a new mechanism for osteoporosis suggested by a transcriptome-wide expression study of monocytes. PLoS One 10, e0116792 (2015).
pubmed: 25659073
pmcid: 4319757
doi: 10.1371/journal.pone.0116792
Morris, J. A. et al. An atlas of genetic influences on osteoporosis in humans and mice. Nat. Genet. 51, 258–266 (2019).
pubmed: 30598549
doi: 10.1038/s41588-018-0302-x
Coates, B. A. et al. Transcriptional profiling of intramembranous and endochondral ossification after fracture in mice. Bone 127, 577–591 (2019).
pubmed: 31369916
pmcid: 6708791
doi: 10.1016/j.bone.2019.07.022
Balwierz, P. J. et al. ISMARA: automated modeling of genomic signals as a democracy of regulatory motifs. Genome Res. 24, 869–884 (2014).
pubmed: 24515121
pmcid: 4009616
doi: 10.1101/gr.169508.113
Ikeda, F. et al. Critical roles of c-Jun signaling in regulation of NFAT family and RANKL-regulated osteoclast differentiation. J. Clin. Invest. 114, 475–484 (2004).
pubmed: 15314684
pmcid: 503767
doi: 10.1172/JCI200419657
Omata, Y. et al. Interspecies single-cell RNA-seq analysis reveals the novel trajectory of osteoclast differentiation and therapeutic targets. JBMR Plus 6, e10631 (2022).
pubmed: 35866155
pmcid: 9289986
doi: 10.1002/jbm4.10631
Musa, J., Aynaud, M. M., Mirabeau, O., Delattre, O. & Grunewald, T. G. MYBL2 (B-Myb): a central regulator of cell proliferation, cell survival and differentiation involved in tumorigenesis. Cell Death Dis. 8, e2895 (2017).
pubmed: 28640249
pmcid: 5520903
doi: 10.1038/cddis.2017.244
Signorelli, M., Vinciotti, V. & Wit, E. C. NEAT: an efficient network enrichment analysis test. BMC Bioinformatics 17, 352 (2016).
pubmed: 27597310
pmcid: 5011912
doi: 10.1186/s12859-016-1203-6
McDonald, M. M. et al. Osteoclasts recycle via osteomorphs during RANKL-stimulated bone resorption. Cell 184, 1330–1347.e1313 (2021).
pubmed: 33636130
pmcid: 7938889
doi: 10.1016/j.cell.2021.02.002
Hauser, A. S., Attwood, M. M., Rask-Andersen, M., Schioth, H. B. & Gloriam, D. E. Trends in GPCR drug discovery: new agents, targets and indications. Nat. Rev. Drug Discov. 16, 829–842 (2017).
pubmed: 29075003
pmcid: 6882681
doi: 10.1038/nrd.2017.178
Diepenhorst, N. et al. G protein-coupled receptors as anabolic drug targets in osteoporosis. Pharmacol. Ther. 184, 1–12 (2018).
pubmed: 29080701
doi: 10.1016/j.pharmthera.2017.10.015
Luo, J., Sun, P., Siwko, S., Liu, M. & Xiao, J. The role of GPCRs in bone diseases and dysfunctions. Bone Res. 7, 19 (2019).
pubmed: 31646011
pmcid: 6804689
doi: 10.1038/s41413-019-0059-6
Chambers, T. J. & Moore, A. The sensitivity of isolated osteoclasts to morphological transformation by calcitonin. J. Clin. Endocrinol. Metab. 57, 819–824 (1983).
pubmed: 6193136
doi: 10.1210/jcem-57-4-819
Kooistra, A. J. et al. GPCRdb in 2021: integrating GPCR sequence, structure and function. Nucleic Acids Res. 49, D335–D343 (2021).
pubmed: 33270898
doi: 10.1093/nar/gkaa1080
Luo, J. et al. LGR4 is a receptor for RANKL and negatively regulates osteoclast differentiation and bone resorption. Nat. Med. 22, 539–546 (2016).
pubmed: 27064449
doi: 10.1038/nm.4076
Hauser, A. S. et al. Common coupling map advances GPCR-G protein selectivity. Elife 11, e74107 (2022).
pubmed: 35302494
pmcid: 9005189
doi: 10.7554/eLife.74107
Pandey, S. et al. Partial ligand-receptor engagement yields functional bias at the human complement receptor, C5aR1. J. Biol. Chem. 294, 9416–9429 (2019).
pubmed: 31036565
pmcid: 6579481
doi: 10.1074/jbc.RA119.007485
Kovtun, A. et al. Complement receptors C5aR1 and C5aR2 act differentially during the early immune response after bone fracture but are similarly involved in bone repair. Sci. Rep. 7, 14061 (2017).
pubmed: 29070810
pmcid: 5656620
doi: 10.1038/s41598-017-14444-3
Modinger, Y., Loffler, B., Huber-Lang, M. & Ignatius, A. Complement involvement in bone homeostasis and bone disorders. Semin. Immunol. 37, 53–65 (2018).
pubmed: 29395681
doi: 10.1016/j.smim.2018.01.001
Pobanz, J. M., Reinhardt, R. A., Koka, S. & Sanderson, S. D. C5a modulation of interleukin-1 beta-induced interleukin-6 production by human osteoblast-like cells. J. Periodontal Res. 35, 137–145 (2000).
pubmed: 10929868
doi: 10.1034/j.1600-0765.2000.035003137.x
Gorman, D. M. et al. Development of potent and selective agonists for complement C5a receptor 1 with in vivo activity. J. Med. Chem. 64, 16598–16608 (2021).
pubmed: 34762432
doi: 10.1021/acs.jmedchem.1c01174
Woodruff, T. M. et al. Increased potency of a novel complement factor 5a receptor antagonist in a rat model of inflammatory bowel disease. J. Pharmacol. Exp. Ther. 314, 811–817 (2005).
pubmed: 15879003
doi: 10.1124/jpet.105.086835
Hudson, B. D. et al. The pharmacology of TUG-891, a potent and selective agonist of the free fatty acid receptor 4 (FFA4/GPR120), demonstrates both potential opportunity and possible challenges to therapeutic agonism. Mol. Pharmacol. 84, 710–725 (2013).
pubmed: 23979972
pmcid: 3807074
doi: 10.1124/mol.113.087783
Kim, H. J. et al. G protein-coupled receptor 120 signaling negatively regulates osteoclast differentiation, survival, and function. J. Cell Physiol. 231, 844–851 (2016).
pubmed: 26280807
doi: 10.1002/jcp.25133
Kasonga, A. E., Deepak, V., Kruger, M. C. & Coetzee, M. Arachidonic acid and docosahexaenoic acid suppress osteoclast formation and activity in human CD14
pubmed: 25867515
pmcid: 4395026
doi: 10.1371/journal.pone.0125145
Shimpukade, B., Hudson, B. D., Hovgaard, C. K., Milligan, G. & Ulven, T. Discovery of a potent and selective GPR120 agonist. J. Med. Chem. 55, 4511–4515 (2012).
pubmed: 22519963
doi: 10.1021/jm300215x
Rocheville, M. et al. Subtypes of the somatostatin receptor assemble as functional homo- and heterodimers. J. Biol. Chem. 275, 7862–7869 (2000).
pubmed: 10713101
doi: 10.1074/jbc.275.11.7862
Bo, Q. et al. Structural insights into the activation of somatostatin receptor 2 by cyclic SST analogues. Cell Discov. 8, 47 (2022).
pubmed: 35595746
pmcid: 9122944
doi: 10.1038/s41421-022-00405-2
Clowes, J. A., Allen, H. C., Prentis, D. M., Eastell, R. & Blumsohn, A. Octreotide abolishes the acute decrease in bone turnover in response to oral glucose. J. Clin. Endocrinol. Metab. 88, 4867–4873 (2003).
pubmed: 14557467
doi: 10.1210/jc.2002-021447
Ren, S. G. et al. Functional association of somatostatin receptor subtypes 2 and 5 in inhibiting human growth hormone secretion. J. Clin. Endocrinol. Metab. 88, 4239–4245 (2003).
pubmed: 12970293
doi: 10.1210/jc.2003-030303
Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 15, 550 (2014).
pubmed: 25516281
pmcid: 4302049
doi: 10.1186/s13059-014-0550-8
Cody, J. J. et al. A simplified method for the generation of human osteoclasts in vitro. Int. J. Biochem. Mol. Biol. 2, 183–189 (2011).
pubmed: 21968748
pmcid: 3180092
Sorensen, M. G. et al. Characterization of osteoclasts derived from CD14
pubmed: 17187192
doi: 10.1007/s00774-006-0725-9
Hassan, M. Q. et al. HOXA10 controls osteoblastogenesis by directly activating bone regulatory and phenotypic genes. Mol. Cell Biol. 27, 3337–3352 (2007).
pubmed: 17325044
pmcid: 1899966
doi: 10.1128/MCB.01544-06
Gordon, J. A. et al. Pbx1 represses osteoblastogenesis by blocking Hoxa10-mediated recruitment of chromatin remodeling factors. Mol. Cell Biol. 30, 3531–3541 (2010).
pubmed: 20439491
pmcid: 2897555
doi: 10.1128/MCB.00889-09
Wang, Y. et al. Obesity regulates miR-467/HoxA10 axis on osteogenic differentiation and fracture healing by BMSC-derived exosome LncRNA H19. J. Cell Mol. Med. 25, 1712–1724 (2021).
pubmed: 33471953
pmcid: 7875915
doi: 10.1111/jcmm.16273
Blixt, N. et al. Loss of myocyte enhancer factor 2 expression in osteoclasts leads to opposing skeletal phenotypes. Bone 138, 115466 (2020).
pubmed: 32512162
pmcid: 7443313
doi: 10.1016/j.bone.2020.115466
Leupin, O. et al. Control of the SOST bone enhancer by PTH using MEF2 transcription factors. J. Bone Miner. Res. 22, 1957–1967 (2007).
pubmed: 17696759
doi: 10.1359/jbmr.070804
D’Angelo, R. et al. Inhibition of osteoclast activity by complement regulation with DF3016A, a novel small-molecular-weight C5aR inhibitor. Biomed. Pharmacother. 123, 109764 (2020).
pubmed: 31901551
doi: 10.1016/j.biopha.2019.109764
Toyama, C. et al. Effect of a C5a receptor antagonist on macrophage function in an intestinal transplant rat model. Transpl. Immunol. 72, 101559 (2022).
pubmed: 35227893
doi: 10.1016/j.trim.2022.101559
Levaot, N. et al. Osteoclast fusion is initiated by a small subset of RANKL-stimulated monocyte progenitors, which can fuse to RANKL-unstimulated progenitors. Bone 79, 21–28 (2015).
pubmed: 26008608
doi: 10.1016/j.bone.2015.05.021
Hofland, L. J. & Lamberts, S. W. Somatostatin receptors and disease: role of receptor subtypes. Baillieres Clin. Endocrinol. Metab. 10, 163–176 (1996).
pubmed: 8734455
doi: 10.1016/S0950-351X(96)80362-4
Tulipano, G. et al. Characterization of new selective somatostatin receptor subtype-2 (sst2) antagonists, BIM-23627 and BIM-23454. Effects of BIM-23627 on GH release in anesthetized male rats after short-term high-dose dexamethasone treatment. Endocrinology 143, 1218–1224 (2002).
pubmed: 11897676
doi: 10.1210/endo.143.4.8716
Milligan, G., Shimpukade, B., Ulven, T. & Hudson, B. D. Complex pharmacology of free fatty acid receptors. Chem. Rev. 117, 67–110 (2017).
pubmed: 27299848
doi: 10.1021/acs.chemrev.6b00056
Gendaszewska-Darmach, E., Drzazga, A. & Koziolkiewicz, M. Targeting GPCRs activated by fatty acid-derived lipids in type 2 diabetes. Trends Mol. Med. 25, 915–929 (2019).
pubmed: 31377146
doi: 10.1016/j.molmed.2019.07.003
Carullo, G. et al. GPR120/FFAR4 pharmacology: focus on agonists in type 2 diabetes mellitus drug discovery. J. Med. Chem. 64, 4312–4332 (2021).
pubmed: 33843223
pmcid: 8154576
doi: 10.1021/acs.jmedchem.0c01002
Sorensen, K. V. et al. Effects of delayed-release olive oil and hydrolyzed pine nut oil on glucose tolerance, incretin secretion and appetite in humans. Nutrients 13, 3407 (2021).
pubmed: 34684407
pmcid: 8538272
doi: 10.3390/nu13103407
Kishikawa, A. et al. Docosahexaenoic acid inhibits inflammation-induced osteoclast formation and bone resorption in vivo through GPR120 by inhibiting TNF-alpha production in macrophages and directly inhibiting osteoclast formation. Front. Endocrinol (Lausanne) 10, 157 (2019).
pubmed: 30949128
doi: 10.3389/fendo.2019.00157
Ahn, S. H. et al. Free fatty acid receptor 4 (GPR120) stimulates bone formation and suppresses bone resorption in the presence of elevated n-3 fatty acid levels. Endocrinology 157, 2621–2635 (2016).
pubmed: 27145004
doi: 10.1210/en.2015-1855
Wilson, S. G. et al. Common sequence variation in FLNB regulates bone structure in women in the general population and FLNB mRNA expression in osteoblasts in vitro. J. Bone Miner. Res. 24, 1989–1997 (2009).
pubmed: 19453265
doi: 10.1359/jbmr.090530
Krakow, D. et al. Mutations in the gene encoding filamin B disrupt vertebral segmentation, joint formation and skeletogenesis. Nat. Genet. 36, 405–410 (2004).
pubmed: 14991055
doi: 10.1038/ng1319
Zhou, X. et al. Filamin B deficiency in mice results in skeletal malformations and impaired microvascular development. Proc. Natl. Acad. Sci. USA 104, 3919–3924 (2007).
pubmed: 17360453
pmcid: 1820684
doi: 10.1073/pnas.0608360104
Farrington-Rock, C. et al. Disruption of the Flnb gene in mice phenocopies the human disease spondylocarpotarsal synostosis syndrome. Hum. Mol. Genet. 17, 631–641 (2008).
pubmed: 17635842
doi: 10.1093/hmg/ddm188
Nakayachi, M. et al. Lectin-like oxidized low-density lipoprotein receptor-1 abrogation causes resistance to inflammatory bone destruction in mice, despite promoting osteoclastogenesis in the steady state. Bone 75, 170–182 (2015).
pubmed: 25744064
doi: 10.1016/j.bone.2015.02.025
Schoenmaker, T. et al. Transcriptomic differences underlying the activin-a induced large osteoclast formation in both healthy control and fibrodysplasia ossificans progressiva osteoclasts. Int. J. Mol. Sci. 24, 6822 (2023).
pubmed: 37047804
pmcid: 10095588
doi: 10.3390/ijms24076822
March, D. R. et al. Potent cyclic antagonists of the complement C5a receptor on human polymorphonuclear leukocytes. Relationships between structures and activity. Mol. Pharmacol. 65, 868–879 (2004).
pubmed: 15044616
doi: 10.1124/mol.65.4.868
Shimon, I. et al. Somatostatin receptor subtype specificity in human fetal pituitary cultures. Differential role of SSTR2 and SSTR5 for growth hormone, thyroid-stimulating hormone, and prolactin regulation. J. Clin. Invest. 99, 789–798 (1997).
pubmed: 9045884
pmcid: 507864
doi: 10.1172/JCI119225
Merrild, D. M. et al. Pit- and trench-forming osteoclasts: a distinction that matters. Bone Res. 3, 15032 (2015).
pubmed: 26664853
pmcid: 4665108
doi: 10.1038/boneres.2015.32
Dobin, A. et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics 29, 15–21 (2012).
pubmed: 23104886
pmcid: 3530905
doi: 10.1093/bioinformatics/bts635
Heinz, S. et al. Simple combinations of lineage-determining transcription factors prime cis-regulatory elements required for macrophage and B cell identities. Mol. Cell 38, 576–589 (2010).
pubmed: 20513432
pmcid: 2898526
doi: 10.1016/j.molcel.2010.05.004
Gillespie, M. et al. The reactome pathway knowledgebase 2022. Nucleic Acids Res. 50, D687–d692 (2022).
pubmed: 34788843
doi: 10.1093/nar/gkab1028
Young, M. D., Wakefield, M. J., Smyth, G. K. & Oshlack, A. Gene ontology analysis for RNA-seq: accounting for selection bias. Genome Biol. 11, R14 (2010).
pubmed: 20132535
pmcid: 2872874
doi: 10.1186/gb-2010-11-2-r14
Ritchie, M. E. et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 43, e47 (2015).
pubmed: 25605792
pmcid: 4402510
doi: 10.1093/nar/gkv007
Korotkevich, G., Sukhov, V. & Sergushichev, A. Fast gene set enrichment analysis. bioRxiv, 060012, https://doi.org/10.1101/060012 (2019).
Kavaliauskaite, G. & Madsen, J. G. S. Automatic quality control of single-cell and single-nucleus RNA-seq using valiDrops. NAR Genom. Bioinform. 5, lqad101 (2023).
pubmed: 38025048
pmcid: 10657416
doi: 10.1093/nargab/lqad101
Hao, Y. et al. Integrated analysis of multimodal single-cell data. Cell 184, 3573–3587.e3529 (2021).
pubmed: 34062119
pmcid: 8238499
doi: 10.1016/j.cell.2021.04.048
Soe, K. & Delaisse, J. M. Glucocorticoids maintain human osteoclasts in the active mode of their resorption cycle. J. Bone Miner. Res. 25, 2184–2192 (2010).
pubmed: 20499345
doi: 10.1002/jbmr.113
Hobolt-Pedersen, A. S., Delaissé, J. M. & Søe, K. Osteoclast fusion is based on heterogeneity between fusion partners. Calcif. Tissue Int. 95, 73–82 (2014).
pubmed: 24862648
pmcid: 4048669
doi: 10.1007/s00223-014-9864-5
Moura, S. R. et al. Stage-specific modulation of multinucleation, fusion and resorption by the long non-coding RNA DLEU1 and miR-16 in human primary osteoclasts. bioRxiv, 2023.2010.2024.563436, https://doi.org/10.1101/2023.10.24.563436 (2023).